News

Metrika Shines in 2026 Chartis RiskTech100 Recognition

Metrika Shines in 2026 Chartis RiskTech100 Recognition

Metrika Recognized in Chartis RiskTech100 2026 List

In an exciting development for the financial technology landscape, Metrika has been acknowledged in the esteemed Chartis RiskTech100 list as a 'One to Watch' for 2026. This recognition is particularly noteworthy as it comes in the newly introduced 'Digital Asset Data and Risk Management' category, reflecting the increasing significance of blockchain risk management in traditional financial sectors.

Significance of Digital Asset Risk Management

The growing digital asset ecosystem demands innovative risk management solutions that go beyond conventional frameworks. Metrika's inclusion in the Chartis RiskTech100 illustrates the company’s vital role in fostering operational resilience and effective risk oversight within this rapidly evolving space. As the financial industry embraces digital assets, specialized approaches to risk management have become essential.

Chartis RiskTech100 Overview

The Chartis RiskTech100 is acknowledged as a premier annual report that ranks the foremost risk technology providers globally. This comprehensive assessment, celebrated for its independence and thoroughness, analyzes various facets of risk and compliance technology. The introduction of a distinct category for Digital Asset Data and Risk Management is a testament to the increasing institutional adoption of blockchain-based assets, alongside the intricate challenges that come with them.

Metrika's Groundbreaking Innovations

The recognition from Chartis is underscored by Metrika's development of Integrated Composability Risk (ICR)—an innovative framework designed specifically for managing risks associated with digital assets. As Sidhartha Dash, Chief Researcher at Chartis Research, emphasizes, Metrika is setting new benchmarks by collating technology, operational, regulatory, and interoperability risks into a singular framework. This holistic approach towards quantifying risks is crucial as financial institutions seek to adeptly manage digital asset exposures.

Operationalizing the ICR Framework

Metrika’s platform is designed to meet the urgent demands of financial institutions as they navigate the complexities associated with digital assets. The Metrika Asset Risk Score (MARS) is key to this strategy, translating complicated blockchain data into comprehensible, real-time risk metrics. This tool provides Chief Risk Officers (CROs) with the nuanced visibility necessary to navigate the dynamic landscape of digital asset risk.

The Future of Digital Asset Risk Management

As the cryptocurrency terrain evolves, bringing a wave of regulatory clarity, financial institutions increasingly rely on robust risk frameworks. Metrika’s commitment to this cause not only strengthens its market position but also illustrates a broader industry shift towards recognizing digital assets as a standalone asset class. CEO Nikos Andrikogiannopoulos lauds this recognition, attributing it to Metrika's dedication to integrating advanced solutions that operate seamlessly with existing Governance, Risk Management, and Compliance (GRC) systems.

About Metrika

Metrika stands at the forefront of real-time risk management solutions tailored for the digital asset domain. With a user-friendly SaaS platform, Metrika empowers financial institutions, enterprises, and regulatory stakeholders to effectively oversee, assess, and mitigate risks linked to tokenized assets, stablecoins, cryptocurrencies, and blockchain networks.

By shifting from fragmented, manual risk assessments to structured, automated frameworks, Metrika facilitates enhanced analytics paired with industry-specific Key Risk Indicators (KRIs) dedicated to the ever-evolving digital asset ecosystem. This innovative structure has made Metrika a trusted partner for top financial organizations across the globe, including Global Systemically Important Banks (G-SIBs), asset managers, and regulatory bodies.

About Chartis Research

Chartis Research specializes in offering thorough research and analysis within the global risk technology market. They provide insights into enterprise risk management, governance, risk, and compliance technology markets. With in-depth industry analysis and understanding of vendor capabilities, Chartis is committed to illuminating trends and end-user requirements.

Frequently Asked Questions

What is the Chartis RiskTech100?

The Chartis RiskTech100 is an annual ranking of the top global risk technology providers, recognized as a comprehensive assessment of the industry.

Why is Metrika highlighted in the 2026 RiskTech100?

Metrika is recognized for its innovative Integrated Composability Risk (ICR) framework designed for managing digital asset risks effectively.

What role does Metrika serve in digital asset management?

Metrika provides advanced risk management solutions that enable organizations to monitor and mitigate risks associated with digital assets.

How does Metrika assist financial institutions?

Metrika helps financial institutions by offering real-time analytics and frameworks that enhance their ability to manage and assess digital asset risks.

What future trends are expected in digital asset risk management?

Financial institutions are likely to increase their adoption of solid risk management frameworks for digital assets, driven by regulatory clarity and the growing complexity of digital ecosystems.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 397

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 149

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 205

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 606

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 288

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 245

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 223

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 322

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

Care Synergy and RCC Medical Equipment Launch New Partnership

Updated Category News Views 320

Care Synergy and RCC Medical Equipment Form Joint Venture In an exciting development for healthcare services, Care Synergy and RCC Medical Equipment Co. have announced their plans to create a strategic joint venture aimed at improving healthcare delivery in the Colorado Front Range region. This partnership will leverage the strengths of both organizations to provide...

Continue Reading
Revitalizing China's Tourism with High-Tech Cultural Experiences

Updated Category News Views 217

Revitalizing China's Tourism Through High-Tech Cultural Experiences China's tourism industry is undergoing an exciting transformation, fueled by the innovative use of advanced technology paired with its rich cultural heritage. A remarkable example is in Chongqing Municipality, where the city's skyline has become a vibrant showcase of cultural stories, highlighted by...

Continue Reading
Intriguing Insights into United States Steel Options Trades

Updated Category News Views 111

Analyzing Unusual Options Activity in United States Steel Recently, there's been notable market activity where investors with deep pockets are taking a more bearish stance on United States Steel (X). This trend is definitely something for retail traders to pay attention to, especially when navigating the complexities of the stock market. Today's options history unveiled...

Continue Reading
Mesoblast's Operational Highlights and Financial Insights Unveiled

Updated Category News Views 185

Mesoblast Limited's Webcast for Financial Results On a recent occasion, Mesoblast Limited (NASDAQ: MESO; ASX: MSB), a pioneer in allogeneic cellular medicine for inflammatory diseases, announced a webcast to delve into their operational achievements and financial metrics for the half year concluding December 31, 2024. Details of the Webcast Event The engaging webcast is...

Continue Reading
Investors of DXC Technology Prepare for Class Action Lawsuit

Updated Category News Views 77

Investors of DXC Technology Company Take Action In recent months, investors who purchased common stock from DXC Technology Company (NYSE: DXC) have been given a significant opportunity to participate in a class action lawsuit. This situation arises from allegations of securities fraud that are said to have affected many individuals who bought shares during specific key...

Continue Reading